The prevalence of sight-threatening uveitis in Scotland

Aim: To identify and quantify the prevalence of patients with uveitis receiving systemic immunosuppression in Scotland. Methods: Anonymised data were prospectively collected on all patients with uveitis requiring systemic immunosuppression. Seven health boards participated over a 4-month period between 1 August 2005 and 30 November 2005. Results: 373 patients were identified, of whom 205 (55%) were female. The mean age was 46.4 (range 7–97 years). Using the data from the seven participating health boards, an estimated Scottish prevalence of 9 per 100 000 was calculated. Prevalence varied between 2 and 59 per 100 000. In National Health Service Grampian, all patients with uveitis, whether sight-threatening or not, are followed up at a specialist clinic. Extrapolating this figure to Scotland gives a prevalence of 25 per 100 000. Discussion: The data from National Health Service Grampian suggest that there is a significant shortfall in the number of patients identified by survey. If the “missing population” exists, then where are they? Some might be receiving appropriate treatment at non-specialist clinics, although simple under-reporting may play a part. Greater concern is for those patients receiving inappropriate treatment for their uveitis, or for those within the community who are either oblivious to or in self denial of their condition.

[1]  M. McKibbin,et al.  Patient pathways for macular disease: what will the new optometrist with special interest achieve? , 2007, Eye.

[2]  A. Dick,et al.  Are we still reluctant to immunosuppress? , 2005, Clinical & experimental ophthalmology.

[3]  S. Lightman,et al.  Clinical outcome of chronic immunosuppression in patients with non‐infectious uveitis , 2005, Clinical & experimental ophthalmology.

[4]  D. Gritz,et al.  Incidence and prevalence of uveitis in Northern California , 2004 .

[5]  W. Hodge Incidence and prevalence of uveitis in Northern California: discussion by , 2004 .

[6]  D. Gritz,et al.  Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study. , 2004, Ophthalmology.

[7]  J. Forrester,et al.  Immunosuppressive therapy for chronic uveitis: optimising therapy with steroids and cyclosporin A , 1997, The British journal of ophthalmology.

[8]  A Rothova,et al.  The possible impact of uveitis in blindness: a literature survey. , 1996, The British journal of ophthalmology.

[9]  A. Rothova,et al.  Causes and frequency of blindness in patients with intraocular inflammatory disease. , 1996, The British journal of ophthalmology.

[10]  V. Klauss,et al.  [Cause of blindness in Bavaria. Evaluation of a representative sample from blindness compensation records of Upper Bavaria]. , 1992, Klinische Monatsblatter fur Augenheilkunde.

[11]  R. Nussenblatt The natural history of uveitis , 1990, International Ophthalmology.

[12]  R. Miettinen INCIDENCE OF UVEITIS IN NORTHERN FINLAND , 1977, Acta ophthalmologica.

[13]  D. Wakefield,et al.  Epidemiology of Uveitis , 2005, International ophthalmology clinics.

[14]  J. ten Doesschate Causes of blindness in The Netherlands , 1982, Documenta ophthalmologica. Advances in ophthalmology.

[15]  T. Suie Department of Ophthalmology , 1969 .